Longer breastfeeding along with antiretroviral drugs could lower HIV transmission to babies

April 25, 2012
Shown here are Charles Chasela, PhD, nurse Bertha Chisale, Charles van der Horst, MD (holding a BAN study baby) and the baby's mother. This photo was taken at Kawale Clinic in Lilongwe, Malawi. Credit: Photo by Lisa Chensvold/UNC Institute for Global Health & Infectious Diseases

In early results of a large-scale randomized study published in 2010 and led by researchers from the University of North Carolina at Chapel Hill, giving daily antiretroviral drugs (ART) to HIV-infected moms or their breastfeeding babies for 28 weeks proved safe and effective for preventing mother-to-child HIV transmission through breast milk.

Now it appears that early weaning – stopping breastfeeding before six months – is of little, if any, protective value against transmission nor is it safe for infant survival.

The findings came from the Breastfeeding, Antiretrovirals, and Nutrition (BAN) trial that was conducted in Lilongwe, Malawi, between April 21, 2004 and January 28, 2010. The study involved more than 2,300 HIV-infected breastfeeding mothers and their newborn babies. BAN investigators were from the U.S. Centers for Disease Control and Prevention (CDC), UNC-Chapel Hill, and UNC Project-Malawi in Lilongwe, Malawi.

In 2010, BAN investigators reported early results demonstrating a 74 project reduction in HIV transmission to the breastfeeding babies if they were taking a single daily dose of the antiviral medication nevirapine for 28 weeks. In light of this and other emerging evidence, the World Health Organization in 2010 recommended that be given to either HIV-infected mothers or infants throughout breastfeeding.

A report of the latest and long-term (48 week) BAN outcomes appears in the online edition of The Lancet on April 26, 2012. Here, the researchers focused specifically on the safety and effects of weaning and stopping of maternal or infant ART at 28 weeks after birth. The study's first author is Denise J. Jamieson, MD, MPH from the CDC. Senior author and principal investigator of BAN is Charles van der Horst, MD, a professor in the UNC School of Medicine, Division of infectious diseases.

Jamieson and her BAN colleagues found the overall risk of HIV transmission was significantly greater at 48 weeks (7 percent) in the control group of infants (breastfeeding only) than in the maternal ART group (4 percent) and the infant ART group (4 percent). However, about a third of the infants became HIV infected after most mothers said they had stopped nursing their babies at 28 weeks after giving birth.

"Our 48-week follow-up of women in Malawi has shown that either infant or maternal prophylaxis [with ART] effectively reduces postnatal HIV transmission and that this protective effect persists until after breastfeeding cessation," states Dr. Jamieson. "However, does occur after mothers report that they have weaned their ."

The report also noted that infant illnesses (diarrhea, malaria and TB), growth problems, and deaths significantly increased after early weaning. "Breastfeeding is essential for in Malawi. There should be no early weaning and anti-HIV medications given to the mother or infant should be continued throughout the period," Dr. van der Horst said.

More information: www.thelancet.com/journals/lan … 12)/60321-3/abstract

Related Stories

Recommended for you

Fighting HIV on multiple fronts might lead to vaccine

September 20, 2017
A combination antibody strategy could be the key to halting the spread of HIV, according to results from two promising animal studies.

Three-in-one antibody protects monkeys from HIV-like virus

September 20, 2017
A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived, researchers ...

HIV-AIDS: Following your gut

September 18, 2017
Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have discovered a way to slow viral replication in the gastrointestinal tract of people infected by HIV-AIDS.

Study finds cutbacks in foreign aid for HIV treatment would cause great harm

August 30, 2017
Proposed reductions in U.S. foreign aid would have a devastating impact on HIV treatment and prevention programs in countries receiving such aid, an international team of investigators reports. In their paper published online ...

Cancer drug can reactivate HIV

August 24, 2017
People living with HIV must take a combination of three or more different drugs every day for the rest of their lives. Unfortunately, by following this strict treatment plan, they can suffer from side effects ranging from ...

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.